Advertisement
News
Advertisement

Aegerion publishes Phase 3 results of cholesterol drug

Fri, 11/02/2012 - 12:00am
Mass High Tech: The Journal of New England Technology

Data from a Phase 3 trial of a cholesterol-lowering drug candidate developed by Aegerion Pharmaceuticals, Inc. (Nasdaq:AEGR) was published in an online medical journal Friday, two weeks after an advisory committee of the U.S. Food and Drug Administration voted favorably to approve it.

Advertisement

Share this Story

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading